publication date: Nov. 29, 2016

Immunotherapy Nektar Phase II Study: Anti-tumor activity in 7/18 evaluable patients with solid tumors

Nektar Therapeutics announced that new phase I clinical data for Nektar’s lead immuno-oncology agent, NKTR-214, were presented at the SITC 2016 Annual Meeting. 

NKTR-214 is an investigational immuno-stimulatory therapy designed to expand specific cancer-fighting T cells and Natural Killer cell abundance directly in the tumor micro-environment and increase expression of PD-1 on these immune cells. 

The results were presented by Adi Diab, assistant professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center in an oral presentation during a session entitled “New Cancer Immunotherapy Agents in Development.”

Interim results presented were from the ongoing phase I dose-escalation, first-in-human, trial of single-agent NKTR-214 in patients with locally advanced or metastatic solid tumors, including melanoma, renal cell carcinoma, bladder, colorectal and other solid tumor cancers.

A total of 20 patients were treated in four separate every three-week (q3w) dose cohorts (ranging from 0.003 mg/kg q3w to 0.012 mg/kg q3w) with 18 of these patients evaluable for anti-tumor activity.  Based upon encouraging anti-tumor activity and tolerability of NKTR-214 observed at the 0.006 mg/kg q3w dose, an every two week (q2w) cohort of the 0.006 mg/kg dose began enrolling in September 2016 with an additional 5 patients enrolled to this cohort, all of which … Continue reading CCL Nov 2016 – Nektar Phase II Study: Anti-tumor activity in 7/18 evaluable patients with solid tumors

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.